Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies

Technology appraisal guidance
Reference number: TA171
Published: 18 June 2009
Last updated: 26 June 2019

History

Background information

Multiple myeloma - lenalidomide: review decision - November 2012 information
Appendix A: GE Decision paper
Appendix A: GE Decision paper (PDF 74 KB)

Published:

13 November 2010
Multiple myeloma - lenalidomide: review proposal - March 2012 information
Appendix A: provisional matrix of stakeholders
Appendix A: provisional matrix of stakeholders (PDF 122 KB)

Published:

05 March 2012
Appendix B: proposal paper presented to the Institute's Guidance Executive
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 148 KB)

Published:

05 March 2012
TA171 Multiple myeloma - lenalidomide: review update - November 2011 information
TA171 Multiple myeloma - lenalidomide: review update - January 2011 information

Multiple myeloma - lenalidomide: final appraisal determination

Multiple myeloma - lenalidomide: final appraisal determination information
Multiple myeloma - lenalidomide: final appraisal determination
Multiple myeloma - lenalidomide: final appraisal determination (PDF 132 KB)

Published:

23 April 2009
Response to consultee, commentator and public comments on the ACD and comments from website consultation
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) issued October 2008
Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) issued October 2008 (PDF 154 KB)

Published:

23 April 2009
Response to consultee, commentator and public comments on the second Appraisal Consultation Document (ACD) issued January 2009
Response to consultee, commentator and public comments on the second Appraisal Consultation Document (ACD) issued January 2009 (PDF 145 KB)

Published:

23 April 2009
Letter from the Department of health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma
Letter from the Department of health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma (PDF 24 KB)

Published:

23 April 2009
Letter from Celgene sent on 26th February 2009
Letter from Celgene sent on 26th February 2009 (PDF 30 KB)

Published:

23 April 2009
Consultee and commentator comments on the ACD
Celgene
Celgene (PDF 31 KB)

Published:

23 April 2009
Department of Health
Department of Health (PDF 9.5 KB)

Published:

23 April 2009
Janssen-Cilag
Janssen-Cilag (PDF 59 KB)

Published:

23 April 2009
Macmillan Cancer Relief
Macmillan Cancer Relief (PDF 24 KB)

Published:

23 April 2009
Myeloma UK
Myeloma UK (PDF 33 KB)

Published:

23 April 2009
Royal College of Nursing
Royal College of Nursing (PDF 18 KB)

Published:

23 April 2009
Royal College of Pathologists
Royal College of Pathologists (PDF 135 KB)

Published:

23 April 2009
Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO
Royal College of Physicians on behalf of NCRI/RCP/RCR/ACP/JCCO (PDF 35 KB)

Published:

23 April 2009
Sandwell PCT
Sandwell PCT (PDF 22 KB)

Published:

23 April 2009
UK Myeloma Forum and British Society for Haematology
UK Myeloma Forum and British Society for Haematology (PDF 14 KB)

Published:

23 April 2009
Public comments on the ACD
Public comments on the ACD (PDF 42 KB)

Published:

23 April 2009

Multiple myeloma - lenalidomide: appraisal consultation document 2

Multiple myeloma - lenalidomide: appraisal consultation document 2
Multiple myeloma - lenalidomide: appraisal consultation document 2 information
Multiple myeloma - lenalidomide: comments on the ACD issued in October 2008
Extra analysis
Addendum to the ERG report
Addendum to the ERG report (PDF 110 KB)

Published:

30 January 2009
Addendum to the pre-meeting briefing: end of life - a quantitative exploration
Addendum to the pre-meeting briefing: end of life - a quantitative exploration (PDF 24 KB)

Published:

30 January 2009
Non-manufacturer comments on the ACD issued in October 2008
Department of Health
Department of Health (PDF 6.8 KB)

Published:

30 January 2009
Janssen-Cilag
Janssen-Cilag (PDF 51 KB)

Published:

30 January 2009
Macmillan Cancer Support
Macmillan Cancer Support (PDF 39 KB)

Published:

30 January 2009
Myeloma UK, Leukaemia CARE, Leukaemia Research and the Rarer Cancers Forum
Myeloma UK, Leukaemia CARE, Leukaemia Research and the Rarer Cancers Forum (PDF 66 KB)

Published:

30 January 2009
Royal College of Nursing
Royal College of Nursing (PDF 18 KB)

Published:

30 January 2009
Royal College of Physicians, Medical Oncology Joint Special Committee
Royal College of Physicians, Medical Oncology Joint Special Committee (PDF 22 KB)

Published:

30 January 2009
Royal College of Pathologist
Royal College of Pathologist (PDF 71 KB)

Published:

30 January 2009
Sandwell PCT
Sandwell PCT (PDF 15 KB)

Published:

30 January 2009
UK Myeloma Forum and British Society for Haematology
UK Myeloma Forum and British Society for Haematology (PDF 17 KB)

Published:

30 January 2009
Welsh Assembly Government
Welsh Assembly Government (PDF 12 KB)

Published:

30 January 2009
Manufacturer comments on the ACD issued in October 2008
Celgene response to ACD
Celgene response to ACD (PDF 101 KB)

Published:

30 January 2009
Celgene response to ERG lenalidomide report
Celgene response to ERG lenalidomide report (PDF 160 KB)

Published:

30 January 2009
Letter to DH regarding proposed patient access scheme
Letter to DH regarding proposed patient access scheme (PDF 139 KB)

Published:

30 January 2009
Response to questions from NICE on ACD comments
Response to questions from NICE on ACD comments (PDF 34 KB)

Published:

30 January 2009
NICE letter to Celgene requesting clarification on their ACD response
NICE letter to Celgene requesting clarification on their ACD response (PDF 28 KB)

Published:

30 January 2009
Public comments on the ACD issued in October 2008
Letters
Letters (PDF 1012 KB)

Published:

30 January 2009
Emails
Emails (PDF 92 KB)

Published:

30 January 2009
Web comments
Web comments (PDF 774 KB)

Published:

30 January 2009
Letter to NICE from the Department of Health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma
Letter to NICE from the Department of Health RE: Patient Access Scheme for lenalidomide for the treatment of multiple myeloma (PDF 24 KB)

Published:

30 January 2009

Multiple myeloma - lenalidomide: appraisal consultation

Multiple myeloma - lenalidomide: appraisal consultation
Multiple myeloma - lenalidomide: appraisal consultation document information
Multiple myeloma - lenalidomide: evaluation report
Multiple myeloma - lenalidomide: pre-meeting briefing
Multiple myeloma - lenalidomide: pre-meeting briefing (PDF 133 KB)

Published:

28 October 2008
Multiple myeloma - lenalidomide: evidence review group report
Multiple myeloma - lenalidomide: evidence review group report (PDF 997 KB)

Published:

28 October 2008
Non-manufacturer submissions
Myeloma UK
Myeloma UK (PDF 54 KB)

Published:

28 October 2008
Royal College of Nursing
Royal College of Nursing (PDF 14 KB)

Published:

28 October 2008
Royal College of Physicians (on behalf of the NCRI, RCP, RCR, ACP and JCCO)
Royal College of Physicians (on behalf of the NCRI, RCP, RCR, ACP and JCCO) (PDF 36 KB)

Published:

28 October 2008
Royal College of Pathologists
Royal College of Pathologists (PDF 124 KB)

Published:

28 October 2008
UK Myeloma Forum and British Society For Haematology
UK Myeloma Forum and British Society For Haematology (PDF 125 KB)

Published:

28 October 2008
Manufacturer submission
Celgene
Celgene (PDF 1.44 MB)

Published:

28 October 2008
NICE request for clarification
NICE request for clarification (PDF 288 KB)

Published:

28 October 2008
Response from Celgene to request for clarification: Additional information: Part 1
Response from Celgene to request for clarification: Additional information: Part 1 (PDF 26 KB)

Published:

28 October 2008
Response from Celgene to request for clarification: Additional information: Part 2
Response from Celgene to request for clarification: Additional information: Part 2 (PDF 17 KB)

Published:

28 October 2008
Multiple myeloma - lenalidomide: Response from Celgene to request for clarification
Multiple myeloma - lenalidomide: Response from Celgene to request for clarification (PDF 288 KB)

Published:

28 October 2008
Expert written personal statements
Brown
Brown (PDF 59 KB)

Published:

28 October 2008
Cavenagh
Cavenagh (PDF 45 KB)

Published:

28 October 2008
Low
Low (PDF 18 KB)

Published:

28 October 2008
Schey
Schey (PDF 42 KB)

Published:

28 October 2008

Multiple myeloma - lenalidomide: final scope

Multiple myeloma - lenalidomide: final scope
Multiple myeloma - lenalidomide: final scope (PDF 32 KB)

Published:

12 May 2008

Multiple myeloma - lenalidomide: draft scope (pre-referral)

Multiple myeloma - lenalidomide: draft scope (pre-referral)
Multiple myeloma - lenalidomide: draft scope (pre-referral) (PDF 34 KB)

Published:

12 May 2008

Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral)

Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral)
Multiple myeloma - lenalidomide: response to comments on the draft scope (pre-referral) (PDF 147 KB)

Published:

12 May 2008

Multiple myeloma - lenalidomide: provisional matrix of consultees and commentators

Multiple myeloma - lenalidomide: provisional matrix of consultees and commentators
Multiple myeloma - lenalidomide: provisional matrix of consultees and commentators (PDF 30 KB)

Published:

10 September 2008

Multiple myeloma - lenalidomide: response to comments on provisional matrix of consultees and commentators

Multiple myeloma - lenalidomide: response to comments on provisional matrix of consultees and commentators
Multiple myeloma - lenalidomide: response to comments on provisional matrix of consultees and commentators (PDF 51 KB)

Published:

12 May 2008